If you have been reading about reversed-phase HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved in the US, EU and Australia | Sale and import restricted; no licensed product |
| Typical test matrices | Urine, serum, seized powder | Urinary detection window is short |
| Primary identification method | LC-MS/MS against a reference standard | High-resolution mass used for confirmation |
| Data sources in the literature | Small trials, case reports, pharmacovigilance | No registrational trial dataset exists |
| Common marketing names | Melanotan 2, MT-II, MT-2 | Label content may not match declared peptide |
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
== Interactions == Lenvatinib inhibits the liver enzyme CYP3A, which also happens to be a metabolic enzyme for the drug. It inhibits the UDP-glucuronosyltransferases UGT1A1 and UGT1A4. Lenvatinib induces CYP3A but not UGT1A1 and UGT1A4. Use of other drugs, especially ones metabolized by the liver enzyme CYP3A, should be monitored in case their plasma concentration changes. In vitro studies have shown that lenvatinib inhibits organic anion transporters 1 and 3 (OAT1 and OAT3). Sunitinib is metabolized in the liver by CYP3A4. It interacts with inducers and inhibitors of CYP3A4 leading to a decrease or increase in the plasma concentration of particular drugs metabolized by the same pathway. It will not change the amount of drug metabolized by the enzyme, because it does not inhibit or induce the enzyme directly. Sunitinib is a substrate of P-glycoprotein and ABCG2 transporters. It acts as an inhibitor for both transporters, especially for ABCG2. Therefore, drugs that are substrates of these carriers will have modified pharmacokinetics. Plasma concentration of sorafenib and paclitaxel may be increased when the drugs are co-administered along with carboplatin. This has no effect on carboplatin. It also increases the AUC of docetaxel, doxorubicin and irinotecan but decreases the AUC of fluorouracil and neomycin, so it is cautionary to administer sorafenib with these drugs as it may alter the plasma concentration. Sorafenib is metabolized by CYP3A4 and UGT1A9. This means that drugs metabolized by these pathways have to be carefully administered.
Significant investment has been made in building road and rail links between Copenhagen and Malmö, Sweden (the Øresund Bridge), and between Zealand and Funen (the Great Belt Fixed Link). The Copenhagen Malmö Port was also formed between the two cities as the common port for the cities of both nations. The main railway operator is Danske Statsbaner (Danish State Railways) for passenger services and DB Schenker Rail for freight trains. The railway tracks are maintained by Banedanmark. Copenhagen has a small Metro system, the Copenhagen Metro and the greater Copenhagen area has an extensive electrified suburban railway network, the S-train. Private vehicles are increasingly used as a means of transport. New cars are taxed by means of a registration tax (85% to 150%) and VAT (25%). The motorway network now covers 1,300 km. Denmark has established a prominent position in the integration of intermittent renewable energy sources, particularly wind power, into its national electricity grid. Building upon this expertise, the country has expanded its strategic focus toward the decarbonization of the transport sector. Central to this initiative is the large-scale integration of plug-in vehicles and the implementation of Vehicle-to-Grid (V2G) technology, which utilizes intelligent battery systems to enhance grid stability and energy storage capacity.
In column chromatography, the column contains a packed column of solid particles, finely ground powders, or gels. This is called the stationary phase or adsorbent. It is most often made of silica gel or alumina. Cellulose powder has often been used in the past. A wide range of stationary phases are available in order to different forms of column chromatographies: ion exchange chromatography, reversed-phase chromatography (RP), affinity chromatography or expanded bed adsorption (EBA). The solid phase may be microporous for an increased surface, though EBA uses a fluidized bed. In general, one should use much more stationary phase than the analyte mixture. For silica column chromatography in particular, for each gram of dry mass of the analyte mixture, there should be 20 to 100 grams of the stationary phase. Using more silica would increase the resolving power of the chromatography, but also make it slower.
Sources: en.wikipedia.org
This new version is designed and optimized for use by high-throughput laboratory automation instruments. In 2017, the company launched LBgard Blood Tubes, which allow collection and preservation of cfDNA for 14 days, and CTCs and WBCs for 4 days, for liquid biopsy and NIPT applications. In 2012, the company began offering custom stabilization services to diagnostic assay manufacturers under the trade name, AssayStable. This service allowed improved manufacturing and stability of diagnostic test kits. After completing several successful contracts with large diagnostic manufacturers, the company launched a related service, PCRstable, that focused specifically on improving stability of PCR-based, molecular diagnostic assays, including those using microfluidic chips and specialized cartridges and cassettes. To facilitate testing and adoption of the company's stabilizers, Biomatrica launched the ReadyDry PCR Stabilizer Screening Kit in 2016.
== Quarks and the mass of a proton == In quantum chromodynamics, the modern theory of the nuclear force, most of the mass of protons and neutrons is explained by special relativity. The mass of a proton is about 80–100 times greater than the sum of the rest masses of its three valence quarks, while the gluons have zero rest mass. The extra energy of the quarks and gluons in a proton, as compared to the rest energy of the quarks alone in the QCD vacuum, accounts for almost 99% of the proton's mass. The rest mass of a proton is, thus, the invariant mass of the system of moving quarks and gluons that make up the particle, and, in such systems, even the energy of massless particles confined to a system is still measured as part of the rest mass of the system. Two terms are used in referring to the mass of the quarks that make up protons: current quark mass refers to the mass of a quark by itself, while constituent quark mass refers to the current quark mass plus the mass of the gluon particle field surrounding the quark. These masses typically have very different values. The kinetic energy of the quarks that is a consequence of confinement is a contribution (see Mass in special relativity). Using lattice QCD calculations, the contributions to the mass of the proton are the quark condensate (~9%, comprising the up and down quarks and a sea of virtual strange quarks), the quark kinetic energy (~32%), the gluon kinetic energy (~37%), and the anomalous gluonic contribution (~23%, comprising contributions from condensates of all quark flavors).
Pretargeting (imaging) is a tool for nuclear medicine and radiotherapy. Imaging studies require a high contrast of target to background. This can be provided by using a biomarker which has a high affinity and specificity for its target (e.g. an antibody).
In mammals, the vulva (pl. vulvas or vulvae) comprises mostly external, visible structures of the female genitalia leading into the interior of the female reproductive tract. For humans, it includes the mons pubis, labia majora, labia minora, clitoris, vestibule, urinary meatus, vaginal introitus, hymen, and openings of the vestibular glands (Bartholin's and Skene's). The folds of the outer and inner labia provide a double layer of protection for the vagina (which leads to the uterus). While the vagina is a separate part of the anatomy, colloquially the term has often been used synonymously with vulva. Pelvic floor muscles support the structures of the vulva. Other muscles of the urogenital triangle also give support. Blood supply to the vulva comes from the three pudendal arteries. The internal pudendal veins give drainage. Afferent lymph vessels carry lymph away from the vulva to the inguinal lymph nodes. The nerves that supply the vulva are the pudendal nerve, perineal nerve, ilioinguinal nerve and their branches. Blood and nerve supply to the vulva contribute to the stages of sexual arousal that are helpful in the reproduction process. Following the development of the vulva, changes take place at birth, childhood, puberty, menopause and post-menopause. There is a great deal of variation in the appearance of the vulva, particularly in relation to the labia minora. The vulva can be affected by many disorders, which may often result in irritation. Vulvovaginal health measures can prevent many of these. Other disorders include a number of infections and cancers.
Sources: en.wikipedia.org
Subclass Nautiloidea: Fundamental ectocochliate cephalopods that provided the source for the Ammonoidea and Coleoidea. Order † Plectronocerida: the ancestral cephalopods from the Cambrian Period Order † Ellesmerocerida (500 to 470 Ma) Order † Endocerida (485 to 430 Ma) Order † Actinocerida (480 to 312 Ma) Order † Discosorida (482 to 392 Ma) Order † Pseudorthocerida (432 to 272 Ma) Order † Tarphycerida (485 to 386 Ma) Order † Oncocerida (478.5 to 324 Ma) Order Nautilida (extant; 410.5 Ma to present) Order † Orthocerida (482.5 to 211.5 Ma) Order † Ascocerida (478 to 412 Ma) Order † Bactritida (418.1 to 260.5 Ma) Subclass † Ammonoidea: ammonites (479 to 66 Ma) Order † Goniatitida (388.5 to 252 Ma) Order † Ceratitida (254 to 200 Ma) Order † Ammonitida (215 to 66 Ma) Subclass Coleoidea (410.0 Ma-Rec) Cohort † Belemnoidea: Belemnites and kin Genus † Jeletzkya Order † Aulacocerida (265 to 183 Ma) Order † Phragmoteuthida (189.6 to 183 Ma) Order † Hematitida (339.4 to 318.1 Ma) Order † Belemnitida (339.4 to 66 Ma) Genus † Belemnoteuthis (189.6 to 183 Ma) Cohort Neocoleoidea Superorder Decapodiformes (also known as Decabrachia or Decembranchiata) Order Spirulida: ram's horn squid Order Sepiida: cuttlefish Order Sepiolida: pygmy, bobtail and bottletail squid Order Idiosepida Order Oegopsida: neritic squid Order Myopsida: coastal squid Order Bathyteuthida Superorder Octopodiformes (also known as Vampyropoda) Family † Trachyteuthididae Order Vampyromorphida: vampire squid Order Octopoda: octopus Superorder † Palaeoteuthomorpha Order † Boletzkyida Other classifications differ, primarily in how the various decapod orders are related, and whether they should be orders or families.
The reign of Justinian I was a high point in east Roman history. Following his accession in 527, the legal code was rewritten as the Corpus Juris Civilis, which streamlined Roman law across the empire; he reasserted imperial control over religion and morality through purges of pagans, heretics, and other "deviants"; and having ruthlessly subdued the 532 Nika revolt he rebuilt much of Constantinople, including the Hagia Sophia. Justinian I took advantage of the confusion, following Theoderic the Ostrogoth's death, to attempt the reconquest of Italy. The Vandal Kingdom in North Africa was subjugated in late 533 by the general Belisarius, who then invaded Italy; the Ostrogothic Kingdom mostly ended in 554. In the 540s, Justinian began to suffer reversals on multiple fronts. Capitalising on Constantinople's preoccupation with the West, Khosrow I of the Sasanian Empire invaded Byzantine territory and sacked Antioch in 540. A devastating plague killed a large proportion of the population and severely reduced the empire's social and financial stability. The most difficult period of the Ostrogothic war, against their king Totila, came during this decade; while divisions among Justinian's advisors undercut the administration's response. He also did not fully heal the divisions in Chalcedonian Christianity, as the fifth ecumenical council failed to make a real difference. Justinian died in 565; his reign was more successful than any other emperor, yet he left behind an unstable empire. Justin II (r. 565–578) inherited an empire stretched thin both financially and territorially.
Envenomation resulted in 57,000 human deaths in 2013, down from 76,000 deaths in 1990. Venoms, found in over 173,000 species, have potential to treat a wide range of diseases, explored in over 5,000 scientific papers. In medicine, snake venom proteins are used to treat conditions including thrombosis, arthritis, and some cancers. Gila monster venom contains exenatide, used to treat type 2 diabetes. Solenopsins extracted from fire ant venom has demonstrated biomedical applications, ranging from cancer treatment to psoriasis. A branch of science, venomics, has been established to study the proteins associated with venom and how individual components of venom can be used for pharmaceutical means.
Another phenotype, Muscle-eye-brain disease (MEB) is the dystroglycanopathy most prevalent in Finland, and is caused by mutations in the POMGnT1, FKRP, FKTN, ISPD, and TMEM5 genes. The POMGnT1 gene is expressed in the same tissues as FKTN, and MEB appears to have a similar severity as FCMD. However, symptoms unique to MEB include glaucoma, atrophy of the optic nerves, and retinal generation. The least severe phenotype of dystroglycanopathies is CMD type 1c (MDC1C), caused by mutations in the FKRP and the LARGE gene, with a phenotype similar to MEB and WWS. MDC1C also includes Limb-Girdle muscular dystrophy.
== Return, illness, and death == In 1999, the Panamanian government had sought the extradition of Noriega from the U.S., as he had been tried in absentia and found guilty of murder in Panama in 1995. After Noriega was imprisoned in France, Panama asked the French government to extradite Noriega so he could face trial for human rights violations in Panama. The French government had previously stated that extradition would not happen before the case in France had run its course. On September 23, 2011, a French court ordered a conditional release for Noriega to be extradited to Panama on October 1, 2011. Noriega was extradited to Panama on December 11, 2011, and incarcerated at El Renacer prison to serve the sentences, totalling 60 years, that he had accumulated in absentia for crimes committed during his rule. On February 5, 2012, Noriega was moved to Hospital Santo Tomás in Panama City because of high blood pressure and a brain hemorrhage. He remained in the hospital for four days before being returned to prison. It was announced on March 21, 2012, that Noriega had been diagnosed with a brain tumor, which was later revealed to have been benign. On January 23, 2017, he was released from prison and placed under house arrest to prepare for surgery that would remove the tumor. On March 7, 2017, he suffered a brain hemorrhage during surgery which left him in critical condition in the intensive care unit of Hospital Santo Tomás. Noriega died on May 29, 2017, at the age of 83.
Sources: en.wikipedia.org
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.
Reversed-phase LC-MS/MS is the usual approach for both identification and quantitation. High-resolution mass spectrometry and peptide mapping serve as confirmatory methods. Immunoassays are rarely used alone because of cross-reactivity.
Published testing of seized and purchased samples frequently reports discrepancies between declared and measured peptide content. Counter-ion content and residual solvents add further variation. Independent analysis is the only way to confirm composition.
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.